• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Entera Bio Ltd.

    5/30/25 4:09:04 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ENTX alert in real time by email
    S-8 1 zk2533224.htm S-8
    As filed with the Securities and Exchange Commission on May 30, 2025
    Registration No. 333-_____


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM S-8
     


    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933


     
    Entera Bio Ltd.
    (Exact name of registrant as specified in its charter)
     
    State of Israel
    Not Applicable
    (State or other jurisdiction of incorporation or organization)
    (I.R.S. Employer Identification No.)
       
    Kiryat Hadassah
    Minrav Building – Fifth Floor
    Jerusalem, Israel
    (Address of Principal Executive Offices)
     
    9112002
    (Zip Code)

    Entera Bio Ltd. 2018 Equity Incentive Plan

    (Full title of the plan)

    Gerald Lieberman
    Director
    19 Old Woods Drive
    Harrison, New York 10528

    (Name and address of agent for service)

    (917) 684-1558

    (telephone number, including area code, of agent for service)



    Copies to:

    Drew M. Altman, Esq.
    Sami B. Ghneim, Esq.
    Greenberg Traurig, P.A.
    333 S.E. 2nd Avenue, Suite 4400
    Miami, Florida 33131
    (305) 579-0500

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:
     
    Large accelerated filer
    ☐
    Accelerated filer

    ☐
    Non-accelerated filer
    ☒
    Smaller reporting company

    ☒
       
    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐


    STATEMENT OF INCORPORATION BY REFERENCE
     
    This Registration Statement is filed by Entera Bio Ltd. (the “Registrant”) for the purpose of registering additional ordinary shares, par value NIS 0.0000769 per share (“Ordinary Shares”), of the Registrant under the Entera Bio Ltd. 2018 Equity Incentive Plan (the “Plan”).
     
    The number of Ordinary Shares available for issuance under the Plan is subject to an automatic annual increase on the first day of each calendar year during the term of the Plan equal to the lesser of (i) five percent (5%) of the number of outstanding Ordinary Shares on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Registrant’s Board of Directors (the “Board”), in its discretion (the “Evergreen Provision”). Consequently, pursuant to the Evergreen Provision, the number of Ordinary Shares available for issuance under the Plan increased by an aggregate of 1,941,859 shares on January 1, 2025, which shares are registered under this Registration Statement.
     
    Pursuant to Instruction E of Form S-8, the contents of the Registrant’s prior registration statement on Form S-8 registering Ordinary Shares under the Plan (File No. 333-227488) (the “Prior Registration Statement”) is hereby incorporated by reference herein, and the information otherwise required by Form S-8 is omitted, except that the provisions contained in Part II of the Prior Registration Statement are modified as set forth in this Registration Statement.
     
    PART II
     
    Item 3.
    Incorporation of Documents by Reference.
     
    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Securities and Exchange Commission (the “Commission”):
     

    (a)
    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 28, 2025, pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”);
     

    (b)
    The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Commission on May 9, 2025;
     

    (c)
    The Registrant’s Current Report on Form 8-K filed with the Commission on March 17, 2025 (excluding Item 7.01 and Exhibit 99.1 included therein); and
     

    (d)
    The Registrant’s Registration Statement on Form 8-A filed with the Commission on June 25, 2018 (File No. 001-38556), in which there is described the terms, rights and provisions applicable to the Ordinary Shares, including any amendment or report filed for the purpose of updating such description, including the description of the Ordinary Shares filed as Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K filed on March 31, 2023.

    Additionally, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (not including any information furnished under Items 2.02, 7.01 or 9.01 of Form 8-K or any other information that is identified as, or deemed, “furnished” rather than filed, which information is not incorporated by reference herein), prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated herein by reference and to be a part of the Registration Statement from the date of filing of such documents. Any statement contained in a document incorporated herein by reference will be deemed to be modified or superseded for purposes of the Registration Statement to the extent that a statement contained herein, or in a subsequently filed document incorporated herein by reference, modifies or supersedes the statement. Any statement modified or superseded will not be deemed, except as modified or superseded, to constitute a part of the Registration Statement.


    Item 8.          Exhibits.
     
    The following are the exhibits required by Item 601 of Regulation S-K:
     
    Exhibit No.
     
    Description
     
     
    4.1

    Amended and Restated Articles of Association of Entera Bio Ltd. (incorporated by reference to Exhibit 1.1 to the Form 20-F filed with the Commission on March 18, 2021).
     
     
    4.2

    Entera Bio Ltd. 2018 Equity Incentive Plan (incorporated by reference to Exhibit 99 to the Registration Statement on Form S-8 (File No. 333-227488) filed with the Commission on September 24, 2018).
     
     
    5.1*

    Opinion of Herzog Fox & Neeman.
     
     
    23.1*

    Consent of Kesselman & Kesselman, Certified Public Accountants, a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm.
     
     
    23.2*

    Consent of Herzog Fox & Neeman (included in Exhibit 5.1).
     
     
    24.1*

    Power of Attorney (included on signature pages hereto).
     
     
    107*

    Calculation of Filing Fee Tables
     
    * Filed herewith.
     

    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8, and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Jerusalem, State of Israel, on May 30, 2025.
     
      ENTERA BIO LTD.  

         

    By:
    /s/ Miranda Toledano   
     

    Name: Miranda Toledano  

    Title: Chief Executive Officer  


    POWER OF ATTORNEY
     
    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Miranda Toledano and Dana Yaacov-Garbeli, and each of them any of whom may act without joinder of the other, with full power to act as such person’s true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign this Registration Statement, and any and all amendments thereto (including post-effective amendments), and to file the same, with exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agent or his substitute, may lawfully do or cause to be done by virtue hereof.
     
    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

    Signature
     
    Title
     
    Date
             
    /s/ Miranda Toledano          
     
    Chief Executive Officer and Director
     
    May 30, 2025
    Miranda Toledano
     
    (Principal Executive Officer)
     
             
    /s/ Dana Yaacov-Garbeli         
     
    Chief Financial Officer
     
    May 30, 2025
    Dana Yaacov-Garbeli
     
    (Principal Financial and Accounting Officer)
     
             
    /s/ Gerald Lieberman          
     
    Chairman of the Board
     
    May 30, 2025
    Gerald Lieberman
         
             
    /s/ Yonatan Malca          
     
    Director
     
    May 30, 2025
    Yonatan Malca
         
             
    /s/ Sean Ellis          
     
    Director
     
    May 30, 2025
    Sean Ellis
         
             
    /s/ Haya Taitel          
     
    Director
     
    May 30, 2025
    Haya Taitel
         
             
    /s/ Gerald M. Ostrov          
     
    Director
     
    May 30, 2025
    Gerald M. Ostrov
         


    Get the next $ENTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ENTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Entera Bio Ltd.

      SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

      11/20/24 1:48:55 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Entera Bio Ltd.

      SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

      8/20/24 6:01:17 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Entera Bio Ltd. (Amendment)

      SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

      1/16/24 10:45:49 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on Entera Bio with a new price target

      B. Riley Securities initiated coverage of Entera Bio with a rating of Buy and set a new price target of $9.00

      6/16/21 6:22:06 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aegis Capital initiated coverage on Entera Bio with a new price target

      Aegis Capital initiated coverage of Entera Bio with a rating of Buy and set a new price target of $12.00

      3/22/21 10:40:44 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Maxim Group reiterated coverage on Entera Bio with a new price target

      Maxim Group reiterated coverage of Entera Bio with a rating of Buy and set a new price target of $10.00 from $5.00 previously

      3/11/21 12:09:00 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

      JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025. "During Q1 2025, Entera continued to generate intrinsic value with progress across our programs while significantly extending our cash runway into late 2026 via direct investment from marquis investors and our strategic partner, OPKO Health Inc. ("OPKO"). EB613 early mechanistic effects on both trabecular and cortical bone compartments data using 3D-Shaper software analysis was selected for oral presentation out of 1,680 abstracts submit

      5/9/25 4:05:00 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio's EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO

      JERUSALEM, April 15, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced highlights from Dr. Rachel B Wagman's oral presentation at the 2025 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) Congress in Rome entitled "EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY."  EB613 is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34) tablet treatment to support earlier osteoanabolic intervention for postmenopausal women with osteoporosis at high risk

      4/15/25 8:30:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

      JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024.  "2024 was a truly transformational year for Entera. We delivered key data read-outs and advanced each of our oral peptide PTH(1-34), GLP1/Glucagon and GLP2 tablet programs, significantly increased our stockholder value, and efficiently strengthened our balance sheet. To our core team with whom I started this journey in late 2022 as a board member, and to our rapidly expanding ecosystem of premier global advisors, I

      3/28/25 4:05:00 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENTX
    SEC Filings

    See more

    $ENTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form S-8 filed by Entera Bio Ltd.

      S-8 - Entera Bio Ltd. (0001638097) (Filer)

      5/30/25 4:09:04 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Entera Bio Ltd.

      S-3 - Entera Bio Ltd. (0001638097) (Filer)

      5/30/25 4:05:58 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by Entera Bio Ltd.

      PRE 14A - Entera Bio Ltd. (0001638097) (Filer)

      5/14/25 4:08:35 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Gautam Leslie Velka

      3 - Entera Bio Ltd. (0001638097) (Issuer)

      5/20/25 4:30:18 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Operating Officer Galitzer Hillel was granted 26,316 units of Ordinary Shares, increasing direct ownership by 41% to 90,573 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      4/30/25 4:22:04 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Lieberman Gerald M exercised 23,952 units of Ordinary Shares at a strike of $1.00, increasing direct ownership by 9% to 300,160 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      4/3/25 4:06:27 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

      JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025. "During Q1 2025, Entera continued to generate intrinsic value with progress across our programs while significantly extending our cash runway into late 2026 via direct investment from marquis investors and our strategic partner, OPKO Health Inc. ("OPKO"). EB613 early mechanistic effects on both trabecular and cortical bone compartments data using 3D-Shaper software analysis was selected for oral presentation out of 1,680 abstracts submit

      5/9/25 4:05:00 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

      JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company"), a leader in the development of orally delivered peptides and small therapeutic proteins, today announced the appointment of Rachel B Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board. Dr. Wagman brings more than 20 years of metabolic bone disease and women's health research and drug development experience to Entera. She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo®), denosumab (Prolia®) and romosozumab (Evenity®) through clinical development, registration, and lifecycle mana

      5/15/24 8:00:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

      JERUSALEM, June 07, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it has appointed Haya Taitel, Head of Sanofi's Global Transplant Franchise as an independent director to the Company's Board of Directors. "We are thrilled that Haya has joined our Board," said Miranda Toledano, Chief Executive Officer of Entera. "With more than 30 years of experience building industry-leading commercial organizations across big pharma and biotech, Haya brings a veteran and unique perspective to Entera's Board of Directors. We believe that Haya's track record shepherd

      6/7/23 7:30:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Taitel Haya bought $9,405 worth of Ordinary Shares (9,500 units at $0.99), increasing direct ownership by 37% to 35,115 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      1/16/24 8:00:12 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taitel Haya bought $5,864 worth of Ordinary Shares (7,615 units at $0.77), increasing direct ownership by 42% to 25,615 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      1/11/24 6:14:57 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lieberman Gerald M bought $17,006 worth of Ordinary Shares (23,952 units at $0.71), increasing direct ownership by 12% to 226,961 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      12/27/23 5:00:37 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENTX
    Financials

    Live finance-specific insights

    See more
    • Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

      JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial results for the third quarter of 2022 and provided the following corporate updates. Corporate Updates: Achieved FDA Agreement for Pivotal Study of EB613, the World's First Daily Bone Forming Oral PTH Tablet On October 6th, 2022, Entera announced that it had successfully completed its Type C meeting and reached a record agreement with the U.S. Food and Drug Administration (FDA) that a single pivotal Phase 3 placebo-controlled study could support a New Drug Application (NDA)

      11/10/22 4:15:00 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights

      Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underwayCompany reschedules conference call and webcast to Wednesday, May 18 at 8:00 AM EDT  BOSTON and JERUSALEM, May 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its financial and operating results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Highlights EB613 Clinical Update: Entera's lead clinical candidate, EB613, an oral formulation of human parathyroid hormone (1-34), o

      5/12/22 8:00:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio to Report First Quarter 2022 Financial Results on May 12

      BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report business and financial results for the three months ended March 31, 2022 on Thursday, May 12, 2022 at 8:30 AM EDT. Thursday, May 12, 2022, 8:30 AM EDTDomestic: 877-269-7756International: 201-689-7817Israel: 1809406247Conference ID: 13728252 Webcast: Entera Bio Earnings Webcast A replay of the webcast will be archived on Entera's website for approximately 45 days following the call. About Entera BioEntera is a leader in the development of orally delivered large molecule therapeutics for use in a

      4/28/22 8:00:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care